HPHA — Heidelberg Pharma AG Share News
0.000.00%
Last trade - 00:00- €100.12m
- €133.62m
- €1.46m
Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment (updated)
Brief: Wilex says secures financing commitment from main shareholder Dievini
Brief: Wilex unit Heidelberg Pharma signs license agreement with Max Delbrück Center
Brief: Wilex signs antibody license agreement with Telix Pharmaceuticals Limited
Brief: Wilex subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration
Brief: Wilex 9-month net loss widens to 4.1 mln euros
Brief: Wilex secures further financing with shareholder loan
Brief: Wilex says unit Heidelberg Pharma contracts Suisse CDMO Celonic
Brief: Wilex unit Heidelberg Pharma signs option agreement with Max Delbrück Center
Brief: Wilex H1 net loss up 26 pct at EUR 2.4 mln
Brief: Wilex granted a patent in Europe for the chemical synthesis of dihydroxyisoleucine
Brief: Wilex unit Heidelberg Pharma enters into partnership with Canadian APC
Brief: Wilex Q1 sales revenue and income up at 1.0 mln euros
Brief: Wilex plans rights issue using authorised capital
Brief: Wilex FY net loss widens to 6.6 mln euros
Brief: Wilex: US-Patent Office granted patent for amatoxin conjugates for tumour therapy
Brain AG sets IPO price range at 9 to 12 euros per share
Brief: Wilex successfully completes capital increases
Brief: Wilex adopts capital measures